A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults

NCT00474487 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2831

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Meningitis
Meningococcal Infections

Interventions

BIOLOGICAL: Meningococcal ACWY Polysaccharide Vaccine
BIOLOGICAL: MenACWY CRM (19 to 55 years)
BIOLOGICAL: Meningococcal ACWY Conjugate Vaccine
BIOLOGICAL: Novartis MenACWY Vaccine (56 to 65 Years)

Sponsor

Novartis Vaccines